Pre- and postsurgery behavioral compliance, patient health, and postbariatric surgical weight loss.

Toussi R, Fujioka K, Coleman KJ

Obesity: why be concerned?

Brown WV, Fujioka K, Wilson PW, Woodworth KA

American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient.

Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML, Spitz AF, Apovian CM, Livingston EH, Brolin R, Sarwer DB, Anderson WA, Dixon J, Guven S, American Association of Clinical Endocrinologists, Obesity Society, American Society for Metabolic & Bariatric Surgery

Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.

Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR, APD356-004 Study Group

Rational design of a combination medication for the treatment of obesity.

Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O'Neil P, Schumacher D, Smith D, Dunayevich E, Tollefson GD, Weber E, Cowley MA

Executive summary of the recommendations of the American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient.

Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML, Guven S, Spitz AF, Apovian CM, Livingston EH, Brolin R, Sarwer DB, Anderson WA, Dixon J, American Association of Clinical Endocrinologists, Obesity Society, American Society for Metabolic & Bariatric Surgery

Evaluating preoperative weight loss, binge eating disorder, and sexual abuse history on Roux-en-Y gastric bypass outcome.

Fujioka K, Yan E, Wang HJ, Li Z

Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction.

Fujioka K

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C

Pharmacologic treatment options for obesity: current and potential medications.

Fujioka K, Lee MW